Swedish Orphan Biovitrum AB (publ) Market Cap ($18.24 Billion)
Market Cap & Net Worth: Swedish Orphan Biovitrum AB (publ) (SOBI)
Swedish Orphan Biovitrum AB (publ) market cap. Swedish Orphan Biovitrum AB (publ) (ST:SOBI) has a market capitalization of $18.24 Billion (Skr169.53 Billion) as of November 1, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #1352 globally and #21 in its home market, demonstrating a 8.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Swedish Orphan Biovitrum AB (publ)'s stock price Skr490.20 by its total outstanding shares 345845189 (345.85 Million). Also see SOBI cash flow metrics for how efficiently the company converts equity into cash flow.
Swedish Orphan Biovitrum AB (publ) Market Cap History (2015–2026)
Swedish Orphan Biovitrum AB (publ) market cap history from 2015 to 2026. Data shows growth from $4.79 Billion to $18.24 Billion (14.02% CAGR). Check Swedish Orphan Biovitrum AB (publ) stock price for real-time trading data and today's change.
Swedish Orphan Biovitrum AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Swedish Orphan Biovitrum AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Swedish Orphan Biovitrum AB (publ) (SOBI) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.44x
Swedish Orphan Biovitrum AB (publ)'s market cap is 0.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
25.91x
Swedish Orphan Biovitrum AB (publ)'s market cap is 25.91 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.79 Billion | $5.20 Billion | $809.07 Million | 0.73x | 4.69x |
| 2017 | $3.99 Billion | $6.51 Billion | $1.15 Billion | 0.61x | 3.48x |
| 2018 | $6.86 Billion | $9.14 Billion | $2.42 Billion | 0.75x | 2.84x |
| 2019 | $5.49 Billion | $14.25 Billion | $3.30 Billion | 0.39x | 1.66x |
| 2020 | $5.90 Billion | $15.26 Billion | $3.25 Billion | 0.39x | 1.82x |
| 2021 | $6.58 Billion | $15.53 Billion | $2.68 Billion | 0.42x | 2.46x |
| 2022 | $7.67 Billion | $18.79 Billion | $2.64 Billion | 0.41x | 2.91x |
| 2023 | $9.94 Billion | $22.12 Billion | $2.41 Billion | 0.45x | 4.13x |
| 2024 | $11.81 Billion | $26.03 Billion | $3.88 Billion | 0.45x | 3.04x |
| 2025 | $12.39 Billion | $28.24 Billion | $478.00 Million | 0.44x | 25.91x |
Competitor Companies of SOBI by Market Capitalization
Companies near Swedish Orphan Biovitrum AB (publ) in the global market cap rankings as of November 1, 2026. Also see how large is Swedish Orphan Biovitrum AB (publ)'s balance sheet for a full breakdown of the balance sheet.
Key companies related to Swedish Orphan Biovitrum AB (publ) by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Swedish Orphan Biovitrum AB (publ) (2015–2026)
Market capitalization of Swedish Orphan Biovitrum AB (publ) from 2015 to today. Between 2015 and today, Swedish Orphan Biovitrum AB (publ)'s market cap moved from $4.79 Billion to $ 18.24 Billion, with a yearly change of 14.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr18.24 Billion | +47.30% |
| 2025 | Skr12.39 Billion | +4.85% |
| 2024 | Skr11.81 Billion | +18.88% |
| 2023 | Skr9.94 Billion | +29.59% |
| 2022 | Skr7.67 Billion | +16.53% |
| 2021 | Skr6.58 Billion | +11.44% |
| 2020 | Skr5.90 Billion | +7.51% |
| 2019 | Skr5.49 Billion | -19.95% |
| 2018 | Skr6.86 Billion | +71.86% |
| 2017 | Skr3.99 Billion | +5.25% |
| 2016 | Skr3.79 Billion | -20.73% |
| 2015 | Skr4.79 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Swedish Orphan Biovitrum AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.24 Billion USD |
| MoneyControl | $18.24 Billion USD |
| MarketWatch | $18.24 Billion USD |
| marketcap.company | $18.24 Billion USD |
| Reuters | $18.24 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with… Read more